PO.4.75 The anti-BDCA2 antibody biib059 improves joint and skin manifestations in patients with SLE and both active arthritis and rash

• X Huang,
• RF van Vollenhoven,
• K Kalunian,
• N Franchimont,
• VP Werth,
• C Barbey,
• RA Furie,
• H Carroll,
• C Musselli

Affiliations

X Huang

Department of Rheumatology and Immunology, Guangdong Second Provincial General Hospital, Guangzhou, China

RF van Vollenhoven

1Karolinska Institute, Department of Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID)

K Kalunian

UCSD School of Medicine, La Jolla, California, USA

N Franchimont

Department of Rheumatology, University of Liége, Belgium

VP Werth

3Corporal Michael J. Crescenz Veterans Affairs, Medical Centre Philadelphia PA, Philadelphia, USA

C Barbey

6Biogen, Biosimilars Medical/Affiliate Medical Affairs/Neurology, Cambridge, Massachusetts, USA

RA Furie

2Northwell Health ~ Great Neck, New York ~ USA

H Carroll

5Biogen ~ Cambridge, MA ~ USA

C Musselli

5Biogen ~ Cambridge, MA ~ USA